CYCC Share Price Performance
US$7.05
-256.95 (-97.33%)
Price US$7.05
Share PriceUS$7.05
CYCC Community Narratives
There are no narratives available yet.
Recent CYCC News & Updates
Cyclacel Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.87
- Gross Margin
- 100.00%
- Net Profit Margin
- -64,280.00%
- Debt/Equity Ratio
- 0%
Cyclacel Pharmaceuticals, Inc. Competitors
Snowflake Analysis
About CYCC
- Founded
- 1996
- Employees
- n/a
- CEO
- WebsiteView website
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Market Insight
Why today’s lofty prices test investors, and how to stay invested without losing your edge.
Continue reading
Malaysian Market Performance
- 7 Days: 0.2%
- 3 Months: 3.0%
- 1 Year: -4.0%
- Year to Date: -6.3%
In the last week, the market has been flat. The past year hasn't been profitable, with the market dropping 4.0%. Earnings are forecast to grow by 10% annually. Market details ›